In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma.
Antibiotics, Antineoplastic
/ pharmacokinetics
Biological Availability
Biological Transport
Carcinoma, Hepatocellular
/ drug therapy
Cell Line, Tumor
Doxorubicin
/ analogs & derivatives
Drug Carriers
Hep G2 Cells
Humans
Inhibitory Concentration 50
Liposomes
/ chemistry
Liver Neoplasms
/ drug therapy
MCF-7 Cells
Models, Biological
Models, Statistical
Polyethylene Glycols
/ pharmacokinetics
cell model
doxorubicin
hepatocellular carcinoma
intracellular concentration
liposome
physiologically based pharmacokinetic model
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
06 07 2021
06 07 2021
Historique:
received:
04
05
2021
revised:
28
06
2021
accepted:
02
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
29
10
2021
Statut:
epublish
Résumé
Cytostatic effects of doxorubicin in clinically applied doses are often inadequate and limited by systemic toxicity. The main objective of this in vitro study was to determine the anti-tumoral effect (IC
Identifiants
pubmed: 34359887
pii: cells10071717
doi: 10.3390/cells10071717
pmc: PMC8306283
pii:
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Drug Carriers
0
Liposomes
0
liposomal doxorubicin
0
Polyethylene Glycols
3WJQ0SDW1A
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cancerfonden
ID : CAN2017/518
Organisme : Cancerfonden
ID : 201076PjF
Organisme : Cancerfonden
ID : CAN2018/602
Organisme : Svenska Sällskapet för Medicinsk Forskning
ID : S17-0092
Organisme : Vetenskapsrådet
ID : 2018-03301
Organisme : Vetenskapsrådet
ID : 2020-02367
Références
Breast Cancer Res. 2003;5(2):89-95
pubmed: 12631387
J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):235-257
pubmed: 29234936
Clin Cancer Res. 2013 Dec 15;19(24):6766-76
pubmed: 24141627
J Pharmacol Exp Ther. 2013 Nov;347(2):375-87
pubmed: 23995598
Cancer Manag Res. 2019 Nov 21;11:9761-9769
pubmed: 31819614
Bioconjug Chem. 2016 Oct 19;27(10):2225-2238
pubmed: 27547843
Br J Cancer. 1998 May;77(10):1580-5
pubmed: 9635832
Drug Deliv Transl Res. 2020 Feb;10(1):185-191
pubmed: 31482517
Br J Cancer. 1999 Jun;80(7):1005-11
pubmed: 10362108
Breast Cancer Res. 2011 Aug 12;13(4):215
pubmed: 21884641
Nat Mater. 2020 May;19(5):566-575
pubmed: 31932672
Anal Chem. 2003 Jul 1;75(13):3019-30
pubmed: 12964746
Clin Mol Hepatol. 2015 Sep;21(3):230-1
pubmed: 26526818
Liver Int. 2017 Nov;37(11):1688-1696
pubmed: 28481424
J Pharmacol Exp Ther. 2008 Jan;324(1):95-102
pubmed: 17947497
Liver Int. 2015 Feb;35(2):627-35
pubmed: 25040497
J Pharm Sci. 2015 Mar;104(3):1087-98
pubmed: 25561354
Cells. 2021 May 11;10(5):
pubmed: 34064765
Clin Cancer Res. 2001 Feb;7(2):243-54
pubmed: 11234875
Cancer Chemother Pharmacol. 2018 Feb;81(2):291-304
pubmed: 29204687
Br J Pharmacol. 2012 Jan;165(1):120-34
pubmed: 21615726
J Colloid Interface Sci. 2021 Jan 1;581(Pt A):403-416
pubmed: 32771749
Biochem Pharmacol. 1999 Apr 1;57(7):727-41
pubmed: 10075079
Clin Mol Hepatol. 2015 Sep;21(3):257-67
pubmed: 26527121
J Control Release. 2016 Jun 28;232:255-64
pubmed: 27108612
Oncologist. 2020 Jul;25(7):e1127-e1130
pubmed: 32335988
Biomed Microdevices. 2020 Sep 22;22(4):70
pubmed: 32960346
Cell Death Discov. 2017 May 22;3:17026
pubmed: 28580174
Mol Pharm. 2014 Jan 6;11(1):131-44
pubmed: 24171458
J Nucl Cardiol. 2000 Jan-Feb;7(1):53-62
pubmed: 10698235
J Control Release. 2013 Nov 28;172(1):330-340
pubmed: 24012486
Pharmacol Rev. 2016 Jul;68(3):701-87
pubmed: 27363439
Nanomedicine. 2015 Oct;11(7):1841-50
pubmed: 26115641
J Exp Clin Cancer Res. 2018 Sep 3;37(1):211
pubmed: 30176945
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
J Vis Exp. 2020 Aug 7;(162):
pubmed: 32831309
Cancer Res. 2019 Sep 1;79(17):4326-4330
pubmed: 31481419
Mol Pharm. 2016 Apr 4;13(4):1358-65
pubmed: 26950248
Mol Pharm. 2014 Apr 7;11(4):1301-13
pubmed: 24558959
Mol Pharm. 2017 Feb 6;14(2):448-458
pubmed: 27997198
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
J Control Release. 2016 Dec 28;244(Pt A):108-121
pubmed: 27871992
Cancers (Basel). 2019 Jul 20;11(7):
pubmed: 31330834
ACS Appl Mater Interfaces. 2019 Jun 12;11(23):20642-20648
pubmed: 31117436
Cancer Sci. 2015 Oct;106(10):1438-47
pubmed: 26212113
Neoplasia. 2005 Jul;7(7):705-13
pubmed: 16026650
Cancer Chemother Pharmacol. 1996;38(5):439-45
pubmed: 8765437
Cancer Res. 1994 Feb 15;54(4):987-92
pubmed: 8313389
Int J Cancer. 2010 Jul 1;127(1):1-8
pubmed: 20143388
AAPS J. 2018 Aug 30;20(6):96
pubmed: 30167825
J Control Release. 2014 Oct 10;191:105-14
pubmed: 24852095
Br J Cancer. 1999 Feb;79(5-6):838-42
pubmed: 10070878
Biochem Pharmacol. 1985 Mar 1;34(5):593-8
pubmed: 3856430
PLoS One. 2012;7(4):e35949
pubmed: 22563426